47 resultados.
The Center for Immunoassay (CIE) and the Beijing Institute of Technology (BIT) signed in Havana a memorandum of understanding for the creation of a joint laboratory in the Asian country, focused on expanding academic scientific collaboration
Studies published in scientific journals since the beginning of the new coronavirus pandemic suggest the existence of individual genetic factors that may be related to the development of severe symptoms in certain COVID-19 patients
The development of a novel formulation of recombinant human erythropoietin (NeuroEpo) by the Center for Molecular Immunology, in collaboration with others, offers hope in the treatment of this devastating illness
Researchers at the Biopreparations Center have developed a secure means of transportation for viruses, to be used in the collection and transfer of patients' nasopharyngeal and oropharyngeal samples for the diagnosis of COVID-19
Cuba’s Genetic Engineering and Biotechnology Center and the University of Havana have signed an agreement to create a Nano Biomed lab, focused primarily on innovative projects related to the development of pharmaceuticals
The National Defense Council followed up on the progress made in the recovery from the impact of the recent natural phenomena
Cloud bands associated with the system will continue to produce heavy and locally intense rains in the island’s western region
After receiving authorization from the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) and approval from the Ministry of Public Health, a phase II-III clinical trial began at the Institute of Hematology and Immunology
This is also an opportunity to offer the Island's expertise in the development of radiopharmaceuticals and the conduct of clinical trials, as well as in the training of human resources and the exchange of professionals between the two countries
Industrial production has begun of Cuba’s candidate vaccines Soberana 02 and Abdala (CIGB-66), two of the four developed on the island to combat COVID-19, with progress advancing at BioCubaFarma facilities
